SAN FRANCISCO -- An immuno-oncology (IO) regimen for intermediate-stage hepatocellular carcinoma (HCC) significantly extended ...

SAN FRANCISCO -- Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular ...

Transarterial chemoembolization (TACE), a minimally invasive procedure for liver cancer, is an effective treatment strategy for patients with large, asymptomatic, or multifocal hepatocellular ...

Lenvima plus Keytruda with TACE significantly improved progression-free survival in unresectable, non-metastatic hepatocellular carcinoma compared to TACE with placebo. The study reported a median ...

A meta-analysis found that patients with early and intermediate-stage hepatocellular carcinoma who received external beam radiation therapy (EBRT) demonstrated better local control and ...

Tick marks indicate censoring of data. No participants had an albumin-bilirubin grade of 3, so this group has not been included in subgroup definitions here. BCLC=Barcelona Clinic Liver Cancer.

Severe side effects of TACE are related mainly to treatment-induced ischemic damage in the nontumoral liver, since it can precipitate or exacerbate liver failure, especially in cirrhotic patients of ...